Milestone Pharmaceuticals said on Friday the U.S. health regulator had declined to approve its nasal spray to treat a type of ...

The Food and Drug Administration (FDA) has issued a Complete Response Letter to Milestone Pharmaceuticals regarding the New Drug Application (NDA) for ...

CRL focused on CMC; no clinical issues relating to etripamil raised$69.7M in cash, cash equivalents and short-term investments as of December 31, ...

As a result, prophylactic treatment for PSVT often involves taking daily calcium channel blockers (CCBs), such as verapamil or diltiazem. Despite this, PSVT episodes can and do still occur in many ...

Clearing clinical and regulatory hurdles in the development of a fast-acting nasal spray for a heart condition has been a ...

Weill Cornell Medicine, New York Presbyterian Hospital. Milestone hosted a key opinion leader webinar entitled “Learnings from the Field: Managing PSVT and Studying AFib-RVR in the Community ...

Paroxysmal supraventricular tachycardia (PSVT) and paroxysmal atrial fibrillation ... Use should be directly supervised by a cardiologist skilled in treatment of arrhythmias in children.

Milestone Pharmaceuticals said on Friday that the U.S. health regulator had declined to approve its nasal spray to treat a ...

“We are deeply disappointed by the CRL but remain committed to the potential of CARDAMYST as a novel treatment option that can help patients with PSVT. Our team is evaluating the feedback ...